plan b and tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial What to Expect on Tirzepatide: – Discover if You Qualify for

GLP-1 receptor agonists: targeting both hyperglycaemia and disease processes in diabetes

Remember, if you have any concerns about your injection technique or the best sites for you, talk to your healthcare provider for personalized guidance

Primary care/family doctors remained the leading prescribers , while endocrinologists held the second-most prevalent role

Rodrigo R, Prat H, Passalacqua W, Araya J, Guichard C, Bchler JP

With A1C reductions up to 2.24%, tirzepatide offers the most potent glucose-lowering effect of any incretin-based therapy currently available

By Karen OLeary 0 Karen OLeary Karen OLeary is an Associate Research Analysis Editor with Nature Medicine